Business

Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026

Press Release Nicox to Present Data from NCX 470 Phase 3 Studies at American Glaucoma Society (AGS) Annual Meeting 2026February 10, 2026 – release at 7:30 am Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that phase 3 clinical study results, including two podium presentations, will be delivered at the upcoming American Glaucoma Society (AGS) Annual Meeting 2026 (February 19-22, 2026, Rancho Mirage, CA, U.S.A.